Modality
siRNA
MOA
C5i
Target
CD20
Pathway
Proteasome
SchizophreniaGastric Ca
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
~Nov 2022
→ ~Feb 2024
Phase 2
May 2024
→ Mar 2028
Phase 2Current
NCT06698018
2,001 pts·Gastric Ca
2024-05→2028-03·Terminated
2,001 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-031.9y awayPh2 Data· Gastric Ca
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2
Termina…
Catalysts
Ph2 Data
2028-03-03 · 1.9y away
Gastric Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06698018 | Phase 2 | Gastric Ca | Terminated | 2001 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| AKR-4818 | Akero | Approved | CD20 | |
| Peminaritide | iTeos | NDA/BLA | CD20 |